Genetic analyses were performed for diagnostic purposes and no further authorization was required from the Ethical Committee. Informed consents for genetic testing and the publication of significant results were obtained.
The patient underwent firstly array-CGH (comparative genomic hybridization) analysis with the commercial Agilent 2 × 244 kit (following manufacturer’s instructions, using the ADM-2 algorithm for data analysis with Agilent CytoGenomics software) (Agilent Technologies, Santa Clara, CA, USA), with normal results.
A NGS (Next Generation Sequencing) multigene panel to screen 70 genes responsible for chromatinopathies was subsequently performed with a customised HaloPlex Target Enrichment NGS panel (Agilent Technologies, Santa Clara, CA, USA Agilent Technologies) [11 (link)]. Potentially pathogenic variants were confirmed with PCR amplification and Sanger sequencing. DNA from parents was analysed to assess inheritance.
The significance of candidate variants was classified according to the American College of Medical Genetics and Genomics criteria [12 (link)] using InterVar (http://wintervar.wglab.org/), Varsome (https://varsome.com/), CAVA and PMut prediction (http://mmb.pcb.ub.es/PMut/) tools. Sequence variants were described according to the Human Genome Variation Society nomenclature guidelines (https://varnomen.hgvs.org/).
Free full text: Click here